Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Neoplasm Metastasis 2Leukemia, Monocytic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Cancer 1

Interventions

fludarabine phosphate 24Peripheral Blood Stem Cell Transplantation 21Cyclophosphamide 21Busulfan 19Whole-Body Irradiation 15Tacrolimus 15Mycophenolic Acid 13Methotrexate 12ruxolitinib 11Cyclosporine 10Antilymphocyte Serum 10fludarabine 8Melphalan 7peginterferon alfa-2a 6Aspirin 6Filgrastim 5Stem Cell Transplantation 4Radiotherapy 4Imatinib Mesylate 4Hydroxyurea 4Flow Cytometry 4Etoposide 4Decitabine 4Biopsy 4Azacitidine 4Thiotepa 3Surveys and Questionnaires 3Prednisone 3Methylprednisolone 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Polycythemia Vera × Liposomes × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡